May 2010 Br J Cardiol 2010;17:109-10
BJ Cardio Staff
The guideline, jointly developed with the National Clinical Guidelines Centre for Acute and Chronic Conditions, represents a significant change in practice in some key areas of diagnosing acute coronary sydromes (ACS) and angina. The focus of the new guideline is on the diagnosis of chest pain which is suspected to be of cardiac origin, so that appropriate treatment can be provided. It notes that chest pain is experienced by some 20–40% of the general population at some time during their lives, and accounts for up to 1% of visits to GPs, approximately 700,000 visits (5%) to emergency departments and up to 25% of emergency admissions to hosp
May 2010 Br J Cardiol 2010;17:109-10
BJ Cardio Staff
The guidance states: “Although the committee did not change their conclusion that dronedarone is not as effective as other anti-arrhythmic drugs in preventing the recurrence of AF, it accepted evidence that the drug did not lead to an increase in the risk of mortality, unlike the anti-arrhythmics with which it was compared. The Appraisal Committee also noted comments from patients and clinical experts received during consultation on the previous draft that all current anti-arrhythmic drugs, but particularly amiodarone, had side effects which had a significant impact on quality of life with long term use. Overall, the Committee concluded tha
March 2010 Br J Cardiol 2010;17:59-61
BJ Cardio Staff
NICE calculates that an estimated 25,000 people who are admitted to hospital die from preventable VTE each year. The NICE guideline, jointly developed with the National Clinical Guideline Centre for Acute and Chronic Conditions, recommends that all patients should be assessed for risk of developing blood clots on admission to hospital, and then given preventative treatment that suits their individual needs. Options include anticoagulant drugs such as heparin, anti-embolism stockings and foot impulse or pneumatic devices. This advice covers all patients admitted to hospital – including those having day-case procedures – and not just th
March 2010 Br J Cardiol 2010;17:59-61
BJ Cardio Staff
But UK cardiologists and arrhythmia patient/professional groups, led by the Atrial Fibrillation Association and Heart Rhythm UK, have been petitioning to have this draft recommendation overturned. A second NICE meeting on dronedarone was held at the end of February to consider all the comments that have been received, and a final guidance is expected in the next few weeks. As part of the campaign to allow dronedarone to be available for NHS prescription, more than 100 doctors have signed an open letter to NICE setting out reasons why the drug is needed. A Parliamentary Stakeholder Investigation on the issue has been held and a Parliament Earl
January 2007 Br J Cardiol 2007;14:23-8
Timothy Watson, Eduard Shanstila, Gregory Yh Lip
No content available
May 2006 Br J Cardiol 2006;13:216-8
Sanjay Jeyaseelan, Allan D Struthers, Barclay M Goudie, Stuart D Pringle, Frank M Sullivan, Peter T Donnan
No content available
May 2005 Br J Cardiol 2005;12:240-3
Sarah Jarvis
No content available
September 2004 Br J Cardiol 2004;11:339-41
Andrew Owen
No content available
September 2003 Br J Cardiol 2003;10:395-8
Paul Kelly
No content available
For healthcare professionals only
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits
